Overview

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of ruxolitinib (INCB018424) sustained release (SR) formulation in participants with primary myelofibrosis (PMF), post-polycythemia vera MF (PPV-MF), and post-essential thrombocythemia MF (PET-MF).
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Corporation